Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2008

D-Finitive Cell Technologies to Help Sigma Expand Its Regenerative Medicine Offerings

  • Sigma-Aldrich and D-Finitive Cell Technologie have agreed to work together to support the development of 14 regenerative medicine products over a two-year span, with a planned launch of many of these products next year.

    D-Finitive Cell Technologies specializes in providing hematopoietic and neural stem cell products, cell culture media, and growth factors for cells. D-Finitive provides its services to industry and research institutions for the development of specific products and custom applications. Paul Price, Ph.D., CSO, has created many products currently used in the field of cellular research, including both stem and differentiated cells, and has played a key role in the development of formulations for the growth of cells used in the vaccine and bio-production industries, according to the company.

    This collaboration will expand Sigma-Aldrich’s portfolio of research tools for regenerative medicine by adding products like serum-free media for bone marrow and umbilical cord stem cells, mesenchymal stem cells, and neural stem cells; cytokine cocktails for stem cell expansion and differentiation; formulations for cyropreservation of stem cells; and specialized products to conduct clonogenic assays of the various stem cells.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »